Tag Archives: wegovy

Today, November 11th 2023, represents a tipping point in the treatment of obesity. For decades, doctors have viewed obesity as a cosmetic issue, and have resisted treating it with medications due to safety concerns prompted by drugs of old like “Fen-phen” which were released with inadequate safety studies and resulted in harm. Today, for the […]

For the first time in the history of obesity medicine, a drug has been shown to lower the risk of heart attack and stroke by 20%. For decades, doctors have helped patients reduce their cardiovascular risk by prescribing medications for hypertension and high cholesterol. We now know that treating obesity with medication is similarly compelling. […]

Wegovy Novo Nordisk has announced that they are no longer able to meet the demand in the US marketplace for Wegovy. To ensure people on Wegovy can get their medication, they are prioritizing access to the highest strengths (1.7 mg and 2.4 mg), and will be only producing limited amounts of the starting strengths (.25 […]

Semaglutide has been FDA-approved for the treatment of type 2 diabetes in the forms of Ozempic and Rybelsus, and for the treatment of obesity in the form of Wegovy. Tirzepatide has been approved for the treatment of diabetes in the form of Mounjaro. However, many individuals do not have insurance coverage for these medications. We […]

The FDA has approved a very exciting medication called Mounjaro™. Although approved for treatment of type 2 diabetes, a side effect of Mounjaro™ is weight loss. The same molecule, tirzapeptide, is being researched for weight loss as well. Mounjaro™ is the newest in the class of GLP-1 analogues. GLP-1 (glucagon-like peptide 1) is a hormone […]